198 related articles for article (PubMed ID: 32672335)
21. Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer.
Tato-Costa J; Casimiro S; Pacheco T; Pires R; Fernandes A; Alho I; Pereira P; Costa P; Castelo HB; Ferreira J; Costa L
Clin Colorectal Cancer; 2016 Jun; 15(2):170-178.e3. PubMed ID: 26603055
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy.
Sung S; Son SH; Park EY; Kay CS
PLoS One; 2017; 12(3):e0173955. PubMed ID: 28291841
[TBL] [Abstract][Full Text] [Related]
23. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
24. MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy.
Neri E; Guidi E; Pancrazi F; Castagna M; Castelluccio E; Balestri R; Buccianti P; Masi L; Falcone A; Manfredi B; Faggioni L; Bartolozzi C
Eur J Radiol; 2015 Dec; 84(12):2438-43. PubMed ID: 26462793
[TBL] [Abstract][Full Text] [Related]
25. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Inoue Y; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Nov; 41(5):1643-52. PubMed ID: 22923071
[TBL] [Abstract][Full Text] [Related]
27. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
[TBL] [Abstract][Full Text] [Related]
28. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
29. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
30. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
[TBL] [Abstract][Full Text] [Related]
31. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
Huang CY; Chiang SF; Ke TW; Chen TW; Lan YC; You YS; Shiau AC; Chen WT; Chao KSC
Cancer Immunol Immunother; 2018 Apr; 67(4):551-562. PubMed ID: 29270668
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment Mediators CD8
Zaghloul H; Abbas A; Abdulah D
J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
[TBL] [Abstract][Full Text] [Related]
33. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.
Cho H; Kim JE; Hong YS; Kim SY; Kim J; Ryu YM; Kim SY; Kim TW
Oncoimmunology; 2022; 11(1):2148374. PubMed ID: 36451674
[TBL] [Abstract][Full Text] [Related]
35. Possible role of nuclear β-catenin in resistance to preoperative chemoradiotherapy in locally advanced rectal cancer.
Takahashi H; Nakamura K; Usami A; Tsuruta T; Hashimura M; Matsumoto T; Saegusa M
Histopathology; 2017 Aug; 71(2):227-237. PubMed ID: 28370249
[TBL] [Abstract][Full Text] [Related]
36. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
[TBL] [Abstract][Full Text] [Related]
38. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.
Kamran SC; Lennerz JK; Margolis CA; Liu D; Reardon B; Wankowicz SA; Van Seventer EE; Tracy A; Wo JY; Carter SL; Willers H; Corcoran RB; Hong TS; Van Allen EM
Clin Cancer Res; 2019 Sep; 25(18):5561-5571. PubMed ID: 31253631
[TBL] [Abstract][Full Text] [Related]
39. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients.
Agostini M; Zangrando A; Pastrello C; D'Angelo E; Romano G; Giovannoni R; Giordan M; Maretto I; Bedin C; Zanon C; Digito M; Esposito G; Mescoli C; Lavitrano M; Rizzolio F; Jurisica I; Giordano A; Pucciarelli S; Nitti D
Cancer Biol Ther; 2015; 16(8):1160-71. PubMed ID: 26023803
[TBL] [Abstract][Full Text] [Related]
40. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients.
Kim JC; Ha YJ; Roh SA; Cho DH; Choi EY; Kim TW; Kim JH; Kang TW; Kim SY; Kim YS
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):350-7. PubMed ID: 23490283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
